{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:57:12Z","timestamp":1785902232605,"version":"3.56.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","award":["MMRF-2019"],"award-info":[{"award-number":["MMRF-2019"]}],"id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["1364-19"],"award-info":[{"award-number":["1364-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.trecan.2024.06.002","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:28:08Z","timestamp":1720164488000},"page":"733-748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting cancer stem cells in multiple myeloma"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4817-9316","authenticated-orcid":false,"given":"Emine Gulsen","family":"Gunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Gunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2024.06.002_bb0005","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0010","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.trecan.2024.06.002_bb0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.06.002_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.973836","article-title":"Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche","volume":"12","author":"Solimando","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0025","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0030","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2013-07-517136","article-title":"Osteoblastic niche supports the growth of quiescent multiple myeloma cells","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0035","doi-asserted-by":"crossref","first-page":"40496","DOI":"10.18632\/oncotarget.5800","article-title":"Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?","volume":"6","author":"Franqui-Machin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.06.002_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-2797(00)00211-8","article-title":"Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism","volume":"129","author":"Vasiliou","year":"2000","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.trecan.2024.06.002_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488808786734006","article-title":"Aldehyde dehydrogenase as a marker for stem cells","volume":"3","author":"Moreb","year":"2008","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"10.1016\/j.trecan.2024.06.002_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010277","article-title":"Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers","volume":"5","author":"Deng","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2024.06.002_bb0055","doi-asserted-by":"crossref","first-page":"11986","DOI":"10.18632\/oncotarget.2388","article-title":"NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma","volume":"5","author":"Yang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.06.002_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2024.06.002_bb0065","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood.V120.21.2909.2909","article-title":"Clinical drug resistance linked to inter-convertible phenotypic and functional states of tumor-propagating cells in multiple myeloma","volume":"120","author":"Chaidos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0070","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/blood.V95.12.4020","article-title":"Levels of circulating CD19+ cells in patients with multiple myeloma","volume":"95","author":"Rasmussen","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0075","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1158\/1078-0432.CCR-12-0531","article-title":"Stemness of B-cell progenitors in multiple myeloma bone marrow","volume":"18","author":"Boucher","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0080","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2012-06-436220","article-title":"Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma","volume":"121","author":"Chaidos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0085","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","article-title":"RARalpha2 expression confers myeloma stem cell features","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0090","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2008-12-194126","article-title":"RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0095","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1073\/pnas.0611682104","article-title":"Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma","volume":"104","author":"Peacock","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2024.06.002_bb0100","doi-asserted-by":"crossref","first-page":"5726","DOI":"10.1002\/jcp.26506","article-title":"Hedgehog signaling pathway: epigenetic regulation and role in disease and cancer development","volume":"233","author":"Fattahi","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41419-022-04556-8","article-title":"ALCAM regulates multiple myeloma chemoresistant side population","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.trecan.2024.06.002_bb0110","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/onc.2011.195","article-title":"ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma","volume":"30","author":"Singh","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2024.06.002_bb0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","article-title":"The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma","volume":"34","author":"Vrabel","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.trecan.2024.06.002_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2021.08.009","article-title":"Albendazole inhibits NF-kappaB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma","volume":"520","author":"Yi","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2024.06.002_bb0125","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","article-title":"Targeting signalling pathways and the immune microenvironment of cancer stem cells \u2013 a clinical update","volume":"17","author":"Clara","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-023-01439-z","article-title":"The Notch signaling pathway: a potential target for cancer immunotherapy","volume":"16","author":"Li","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0135","first-page":"20","article-title":"The multifunctional role of Notch signaling in multiple myeloma","volume":"7","author":"Sabol","year":"2021","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.trecan.2024.06.002_bb0140","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","article-title":"Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines","volume":"103","author":"Nefedova","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0145","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (review)","volume":"51","author":"Katoh","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0150","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.0305855101","article-title":"Illegitimate WNT signaling promotes proliferation of multiple myeloma cells","volume":"101","author":"Derksen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2024.06.002_bb0155","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","article-title":"Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma","volume":"75","author":"Yang","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0160","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/ijc.29078","article-title":"Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions","volume":"136","author":"Wen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2024.06.002_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-022-01234-2","article-title":"Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma","volume":"15","author":"Swamydas","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0170","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1158\/1541-7786.MCR-19-0487","article-title":"Proinflammatory macrophages promote multiple myeloma resistance to bortezomib therapy","volume":"17","author":"Beyar-Katz","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0175","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12943-019-1011-5","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation","volume":"18","author":"Ai","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.trecan.2024.06.002_bb0180","article-title":"Granulocytic myeloid-derived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9","volume":"6","author":"Wang","year":"2019","journal-title":"Adv. Sci. (Weinh)"},{"key":"10.1016\/j.trecan.2024.06.002_bb0185","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.33371","article-title":"S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma","volume":"148","author":"Wei","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2024.06.002_bb0190","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.7150\/ijms.48244","article-title":"Identification of key genes and pathways in myeloma side population cells by bioinformatics analysis","volume":"17","author":"Yang","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.trecan.2024.06.002_bb0195","article-title":"CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma","volume":"6","author":"Lewinsky","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2024.06.002_bb0200","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1038\/leu.2017.135","article-title":"A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells","volume":"31","author":"Ray","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.760382","article-title":"Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma","volume":"11","author":"Uckun","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0210","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1634\/stemcells.2007-0637","article-title":"Concise review: mesenchymal stem\/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair \u2013 current views","volume":"25","author":"Phinney","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.trecan.2024.06.002_bb0215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2164-8-65","article-title":"The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse","volume":"8","author":"Pedemonte","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1016\/j.trecan.2024.06.002_bb0220","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/leu.2013.27","article-title":"Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4\/SDF-1","volume":"27","author":"Mirandola","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","article-title":"The bone microenvironment in metastasis; what is special about bone?","volume":"27","author":"Bussard","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.trecan.2024.06.002_bb0230","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.06.002_bb0235","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.18632\/oncotarget.650","article-title":"Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in multiple myeloma?","volume":"3","author":"Caraux","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.06.002_bb0240","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41375-023-01896-y","article-title":"Osteocyte-derived exosomes confer multiple myeloma resistance to chemotherapy through acquisition of cancer stem cell-like features","volume":"37","author":"Cheng","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0245","doi-asserted-by":"crossref","first-page":"876","DOI":"10.3892\/ijo.2012.1545","article-title":"Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide","volume":"41","author":"Kawano","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0250","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.3390\/cancers13236136","article-title":"Promising antigens for the new frontier of targeted immunotherapy in multiple myeloma","volume":"13","author":"Cho","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.trecan.2024.06.002_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1370854","article-title":"Targeted therapy for multiple myeloma: an overview on CD138-based strategies","volume":"14","author":"Riccardi","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0260","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41375-018-0222-x","article-title":"TRIM44 promotes quiescent multiple myeloma cell occupancy and survival in the osteoblastic niche via HIF-1alpha stabilization","volume":"33","author":"Chen","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.trecan.2024.06.002_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.08.005","article-title":"Cancer stem cells in multiple myeloma","volume":"277","author":"Ghosh","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2024.06.002_bb0275","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","article-title":"Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications","volume":"117","author":"Jakubikova","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0280","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2005-10-009084","article-title":"ABCG2 expression, function, and promoter methylation in human multiple myeloma","volume":"108","author":"Turner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0285","first-page":"1678","article-title":"The PI3K\/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma","volume":"41","author":"Wang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.trecan.2024.06.002_bb0290","article-title":"PIWIL1 drives chemoresistance in multiple myeloma by modulating mitophagy and the myeloma stem cell population","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0295","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13287-018-0885-2","article-title":"Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles","volume":"9","author":"Shi","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.trecan.2024.06.002_bb0300","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/nnm.12.216","article-title":"Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma","volume":"9","author":"Yang","year":"2014","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.trecan.2024.06.002_bb0305","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.3390\/cancers15225335","article-title":"CD46-ADC reduces the engraftment of multiple myeloma patient-derived xenografts","volume":"15","author":"VanWyngarden","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.trecan.2024.06.002_bb0310","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1172\/JCI88152","article-title":"Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance","volume":"126","author":"Alonso","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2024.06.002_bb0315","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41408-017-0001-3","article-title":"Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells","volume":"7","author":"Muguruma","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2024.06.002_bb0320","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.31041","article-title":"MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling","volume":"142","author":"Tang","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2024.06.002_bb0325","doi-asserted-by":"crossref","first-page":"127","DOI":"10.21873\/anticanres.13088","article-title":"Bortezomibis more effective to side population of RPMI8226 myeloma cells than classical anti-myeloma agents","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056954","article-title":"Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells","volume":"8","author":"Nara","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2024.06.002_bb0335","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/bjh.16477","article-title":"Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt\/beta-catenin pathway","volume":"189","author":"Wang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216019","article-title":"Luteolin inhibits the TGF-beta signaling pathway to overcome bortezomib resistance in multiple myeloma","volume":"554","author":"Li","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2024.06.002_bb0345","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3892\/ijo.2013.2134","article-title":"Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells","volume":"43","author":"Kawano","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0350","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/jnci\/djz159","article-title":"Identification and characterization of tumor-initiating cells in multiple myeloma","volume":"112","author":"Gao","year":"2020","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.trecan.2024.06.002_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.894535","article-title":"Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells","volume":"13","author":"Elbezanti","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.842200","article-title":"Single-cell proteomics and tumor RNAseq identify novel pathways associated with clofazimine sensitivity in PI- and IMiD-resistant myeloma, and putative stem-like cells","volume":"12","author":"Kumar","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0365","first-page":"1","article-title":"Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression","volume":"7","author":"Morimoto","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.trecan.2024.06.002_bb0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0375","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0380","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0385","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"Gamma-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0390","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cam4.3624","article-title":"Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma","volume":"10","author":"Yan","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2024.06.002_bb0395","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0400","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2024.06.002_bb0405","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0410","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/21645515.2015.1046658","article-title":"CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma","volume":"11","author":"Yousef","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.trecan.2024.06.002_bb0415","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41467-020-14619-z","article-title":"CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide","volume":"11","author":"Radhakrishnan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2024.06.002_bb0420","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.06.002_bb0425","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2024.06.002_bb0430","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0435","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bbmt.2015.12.030","article-title":"Targeting CD138\u2212\/CD20+ clonogenic myeloma precursor cells decreases these cells and induces transferable antimyeloma immunity","volume":"22","author":"Lum","year":"2016","journal-title":"Biol. Blood Marrow Transplant"},{"key":"10.1016\/j.trecan.2024.06.002_bb0440","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1007\/s00262-021-02901-y","article-title":"Natural killer cells efficiently target multiple myeloma clonogenic tumor cells","volume":"70","author":"Leivas","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.trecan.2024.06.002_bb0445","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2024.06.002_bb0450","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5562630","article-title":"Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies","volume":"2021","author":"Luanpitpong","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.666561","article-title":"Integrative analysis of gene expression through one-class logistic regression machine learning identifies stemness features in multiple myeloma","volume":"12","author":"Ban","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.trecan.2024.06.002_bb0460","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40164-022-00294-x","article-title":"A novel E-cadherin\/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways","volume":"11","author":"Samart","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0465","first-page":"E2047","article-title":"Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA","volume":"113","author":"Zhang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2024.06.002_bb0470","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.stem.2020.04.009","article-title":"RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia","volume":"27","author":"Shen","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2024.06.002_bb0475","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.7150\/ijbs.64943","article-title":"ALKBH5 promotes multiple myeloma tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and myeloma stem cell phenotype","volume":"18","author":"Yu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.trecan.2024.06.002_bb0480","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0485","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.stem.2020.12.017","article-title":"Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption","volume":"28","author":"Mondala","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2024.06.002_bb0490","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.12951","article-title":"High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells","volume":"166","author":"Wen","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0495","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/ajhp\/zxac091","article-title":"New and emerging pharmacotherapies for the management of multiple myeloma","volume":"79","author":"Moore","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.trecan.2024.06.002_bb0500","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.trecan.2024.06.002_bb0505","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0510","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.stem.2021.04.011","article-title":"CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.trecan.2024.06.002_bb0515","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1089\/scd.2010.0010","article-title":"Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells","volume":"19","author":"Feng","year":"2010","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.trecan.2024.06.002_bb0520","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/leu.2012.78","article-title":"Small molecule antibody targeting HLA class I inhibits myeloma cancer stem cells by repressing pluripotency-associated transcription factors","volume":"26","author":"Ikegame","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0525","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2024.06.002_bb0530","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.exphem.2009.11.008","article-title":"A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients","volume":"38","author":"Kuranda","year":"2010","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0535","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1038\/leu.2012.140","article-title":"CD19\u2212CD45low\/\u2212 CD38high\/CD138+ plasma cells enrich for human tumorigenic myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0540","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.18632\/oncotarget.1145","article-title":"Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival","volume":"4","author":"Reghunathan","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.trecan.2024.06.002_bb0545","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/leu.2013.383","article-title":"ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0550","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s12185-021-03261-0","article-title":"CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence","volume":"115","author":"Serizawa","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0555","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.trecan.2024.06.002_bb0560","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2024.06.002_bb0565","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/cancers14092154","article-title":"CD229 (Ly9) a novel biomarker for B-cell malignancies and multiple myeloma","volume":"14","author":"Roncador","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332400116X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332400116X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:54:10Z","timestamp":1778882050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240580332400116X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":113,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S240580332400116X"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2024.06.002","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cancer stem cells in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2024.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}